Home » Topics » Regulatory » EMA

EMA
RSS

Kombiglyze recommended for approval in E.U.

Sep. 27, 2011

European approval recommended for Levemir as add-on to Victoza

Sep. 27, 2011

Positive CHMP opinion on new indications for Xarelto

Sep. 27, 2011

Gilead Sciences announces CHMP's opinion on Eviplera

Sep. 27, 2011

Optimer Pharmaceuticals and Astellas gain CHMP recommendation for Dificid approval

Sep. 26, 2011

Rasitrio recommended for approval in E.U.

Sep. 26, 2011

CHMP issues opinion on Edarbi for essential hypertension

Sep. 26, 2011

EMA begins review of orlistat-containing antiobesity medicines

Sep. 26, 2011

EMA confirms positive benefit-to-risk balance for Multaq

Sep. 23, 2011

EMA committee recommends extending approval of Levemir

Sep. 23, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...